Print Page   |   Sign In   |   Register
Companies: Antibe Therapeutics, Inc. (ATBPF)

Company Profile

Echelon Wealth Partners
Research Update 11-11-18
Antibe Therapeutics (TSXV-ATE)
Speculative Buy Target Price $1.40

Read Complete Report

Echelon Wealth Partners
Research Update 08-29-18
Antibe Therapeutics (TSXV-ATE)
Speculative Buy Target Price $1.40

Read Complete Report

Echelon Wealth Partners
Research Update 07-03-18
Antibe Therapeutics (TSXV-ATE)
Speculative Buy Target Price $1.40

Read Complete Report

Echelon Wealth Partners
Research Coverage Initiation 04-19-18
Antibe Therapeutics (TSXV-ATE)
Speculative Buy Target Price $1.40

Read Complete Report

Description

Antibe is a commercial-stage healthcare company focused on pain, inflammation and regenerative medicine. Antibe's lead drug, ATB-346, targets the global need for a safer non-steroidal anti-inflammatory drug for chronic pain and inflammation. Antibe's subsidiary, Citagenix Inc., is a leader in the promotion of tissue regenerative products servicing the orthopaedic and dental marketplaces. Citagenix operates in Canada through its direct sales force and internationally via a network of distributors. Antibe is focused on maximizing shareholder value by: (i) growing a portfolio of both pre-approval and commercial assets in the areas of pain, inflammation and regenerative medicine; and (ii) monetizing this portfolio through partnering and commercialization activity.
 

Contact Information

15 Prince Arthur Avenue
Toronto, ONT M5R 1B2  Canada

Financial Reporting/Disclosure

Reporting Status International Reporting: TSX Venture Exchange
Audited Financials Audited
Latest Report Mar 31, 2016 Annual Report
CIK 0001583682
Fiscal Year End 3/31
OTC Marketplace OTCQX International

Profile Data

SIC - Industry Classification 2834 - Pharmaceutical preparations
Business Status Development Stage Company a/o Sep 04, 2014
Incorporated In: Canada
Year of Inc. 2013
Employees 45 a/o Mar 27, 2015

Company Officers/Contacts

Daniel Legault CEO
John Wallace CSO
Alian Wilson CFO
Scott Curtis VP, Business Development
David Vaughan Chief Development Officer
Beth Chin Finance Manager

Company Directors

Walt Macnee Chairman
Roderick Flower
Daniel Legault
Samira Sakhia
John Wallace
 

Service Providers

OTCQX Advisor
Merriman Capital, Inc.
250 Montgomery St.
16th Floor
San Francisco, CA, 94104
USA

Accounting/Auditing Firm
Zeifmans LLP Chartered Accountants
201 Bridgeland Avenue
Toronto, ONT, M6A 1Y7
Canada

Legal Counsel
Not Available
Investor Relations Firm
Not Available
Community Search
Sign In